The abstract is read at the publisher; the summary is JClub's.
In NRG-BR002, adding metastasis-directed ablation to first-line systemic therapy in oligometastatic breast cancer did not improve median PFS (23.0 vs 19.5 months; HR 0.92).
- Why it matters: Metastasis-directed therapy is used for oligometastatic breast cancer, but its benefit during first-line systemic treatment is uncertain.
- What they did: NRG-BR002 randomized 125 eligible patients with ≤4 metastases and controlled primary disease to systemic therapy alone versus systemic therapy plus SBRT or surgery for all visible metastases; PFS was the primary endpoint.
- The result: With 72 PFS events and 29.9 months median follow-up, PFS and OS were not significantly different, and grade 5 toxicities were not observed; routine ablation outside trials is not supported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.